That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

HORSHOLM, DENMARK / ACCESS Newswire / August 20, 2025 / Revenue and earnings for Gubra Group (CPH:GUBRA) have been record-high in the second quarter of 2025 driven by the outlicensing deal with AbbVie ...